As cancer treatment shifts from broad chemotherapy to highly personalized therapies, drug development in oncology is also evolving.
Sarah Alwardt, PhD
Advertisement
Articles by Sarah Alwardt, PhD
Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine.
Advertisement
Latest Updated Articles
AI Will Converge With Physician-Directed CarePublished: January 5th 2019 | Updated:
- Real-World Evidence Should Be Part of Clinical Trials in Oncology
Published: March 28th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5